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Angiotensin II type 1/adenosine A2A 
receptor oligomers: a novel target 
for tardive dyskinesia
Paulo A. de Oliveira  1, James A. R. Dalton2, Marc López-Cano3,4, Adrià Ricarte2, Xavier 
Morató3,4, Filipe C. Matheus1, Andréia S. Cunha1, Christa E. Müller5, Reinaldo N. Takahashi1, 
Víctor Fernández-Dueñas3,4, Jesús Giraldo2, Rui D. Prediger1,6 & Francisco Ciruela3,4
Tardive dyskinesia (TD) is a serious motor side effect that may appear after long-term treatment with 
neuroleptics and mostly mediated by dopamine D2 receptors (D2Rs). Striatal D2R functioning may be 
finely regulated by either adenosine A2A receptor (A2AR) or angiotensin receptor type 1 (AT1R) through 
putative receptor heteromers. Here, we examined whether A2AR and AT1R may oligomerize in the 
striatum to synergistically modulate dopaminergic transmission. First, by using bioluminescence 
resonance energy transfer, we demonstrated a physical AT1R-A2AR interaction in cultured cells. 
Interestingly, by protein-protein docking and molecular dynamics simulations, we described that 
a stable heterotetrameric interaction may exist between AT1R and A2AR bound to antagonists (i.e. 
losartan and istradefylline, respectively). Accordingly, we subsequently ascertained the existence of 
AT1R/A2AR heteromers in the striatum by proximity ligation in situ assay. Finally, we took advantage 
of a TD animal model, namely the reserpine-induced vacuous chewing movement (VCM), to evaluate a 
novel multimodal pharmacological TD treatment approach based on targeting the AT1R/A2AR complex. 
Thus, reserpinized mice were co-treated with sub-effective losartan and istradefylline doses, which 
prompted a synergistic reduction in VCM. Overall, our results demonstrated the existence of striatal 
AT1R/A2AR oligomers with potential usefulness for the therapeutic management of TD.
Angiotensin II (AII) is a peptidic hormone that causes vasoconstriction through activation of angiotensin recep-
tor type 1 (AT1R). Indeed, it is a key component of the renin-angiotensin system (RAS), which regulates blood 
pressure1. Accordingly, blocking AT1Rs with selective antagonists (i.e. losartan) constitutes the first-line therapy 
to deal with hypertensive patients2. Interestingly, AII is also synthesized in the brain, where its levels are much 
higher than those observed in plasma3. In addition, AT1Rs are expressed both in neurons and glial cells4. Thus, 
the existence of an endogenous brain angiotensin system has been postulated, which may respond to AII synthe-
sized in and/or transported into the brain (for review see ref. 5). The function of AII in the brain has still not been 
fully elucidated. However, a role in the control of stress reaction and cerebral circulation, and in the mechanisms 
leading to brain ischemia, neuronal injury and inflammation has been demonstrated5. In addition, AT1R blockade 
reduced brain inflammation responses6 and had beneficial effects in processes involving microglial activation 
and neuroinflammation (such as animal models of Alzheimer’s disease, brain ischemia and multiple sclerosis) 
(for review see ref. 7). Similarly, in animal models of parkinsonism induced by neurotoxins 6-hydroxydopamine 
(6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), an increase in AII levels, with concomi-
tant AT1R overactivation, has been observed8–10. On the other hand, the presence of RAS components in the basal 
ganglia in general and in the nigrostriatal system in particular has also been reported. Altogether, it has been 
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postulated that brain RAS may be involved in dopaminergic degeneration, especially when the dopaminergic 
system is impaired, thus contributing to the pathogenesis and progression of dopaminergic-related pathologies 
such as Parkinson’s disease (PD).
The concept that cell surface receptors may physically interact forming oligomers appeared early in the eight-
ies, while characterizing G protein-coupled receptors (GPCRs) for neurotransmitters11, 12. Notably, striatal dopa-
minergic receptors in general, and the dopamine D2 receptor (D2R) in particular, constitute the archetypal GPCR 
capable of forming receptor-receptor complexes. Indeed, the potential impact of these oligomers in pathophysi-
ological conditions involving dopaminergic dysfunction has been extensively studied. Interestingly, the D2R has 
been shown to oligomerize with several GPCRs13, including the adenosine A2A receptor (A2AR)14. The D2R-A2AR 
heteromer is expressed in GABAergic striatopallidal neurons and a reciprocal negative allosteric receptor-receptor 
interaction is defined as its “biochemical fingerprint”15. Noteworthy, the D2R-A2AR heteromer has been defined 
as a potential pharmacological target for pathologies associated with dysfunctional dopaminergic signaling, such 
as PD and schizophrenia. Indeed, A2AR antagonists (i.e. istradefylline) are currently used for PD treatment in 
Japan16. On the other hand, the D2R has also been shown to oligomerize with the AT1R in the striatum17, thus the 
potential use of AT1R ligands to modulate dopaminergic signaling has been postulated. Interestingly, early studies 
also indicated interactions between the adenosinergic and the angiotensinergic systems, for instance the antino-
ciceptive effect of AII was related to that produced by adenosine A1 receptor agonists18. In addition, an A2AR- and 
AT1R-mediated synergistic interaction in the peripheral RAS was described19, 20. Thus, while adenosine was able 
to reverse the stimulatory effect of AII on Na+-ATPase activity in the renal proximal tubules via A2AR activation21, 
A2AR blockers reduced AII-mediated ROS formation via Nox2 (NADPH complex enzyme) in endothelial cells20. 
Conversely, AII potentiated the adenosine-induced contraction of afferent arterioles22, while losartan-mediated 
AT1R blockade abolished the adenosine-mediated reflex sympatho-excitatory response in the brachial artery23. 
Altogether, the aforementioned evidence highlights the need for a better understanding of the adenosinergic 
system-RAS interaction. Furthermore, this interaction may be relevant not only in the periphery but also in the 
brain, where a functional interplay with the dopaminergic system may occur.
Here, we study the possible existence, both in cultured cells and in mouse striatum, of a physical AT1R-A2AR 
interaction, which may be a potential target for managing dopaminergic-related disorders (i.e. tardive dyskinesia, 
TD). Also, we seek to characterize the most likely heteromeric receptor arrangement through protein-protein 
docking and long-timescale molecular dynamics (MD) simulations. Finally, we propose a novel multimodal treat-
ment for TD based on the use of AT1R and A2AR antagonists at sub-effective doses, and test it in a mouse TD 
model, namely the reserpine-induced vacuous chewing movement (VCM).
Results
AT1R and A2AR form heteromers in cultured cells. Based on the existence of AT1R/D2R heteromers17, 
we aimed to elucidate whether AT1R is also able to oligomerize with the A2AR, a well-known D2R partner24. To 
this end, we first assessed the co-distribution of AT1R and A2AR in cultured cells through the fluorescence detec-
tion of CFP/YFP tagged receptors. Thus, by means of confocal microscopy analysis of HEK-293T cells transiently 
expressing AT1RCFP and A2ARYFP, a high overlapping in the distribution of the former receptors was observed 
(Fig. 1a). Next, we examined the possible physical interaction of AT1R and A2AR in living cells by means of the 
BRET approach. Thus, cells were transiently transfected with receptor constructs carrying the appropriate fluoro-
phore pairs (A2ARRluc and AT1RYFP). A positive and saturable BRET signal was observed in cells co-transfected 
with a constant concentration of the A2ARRluc and increasing concentrations of AT1RYFP (Fig. 1b). Of note, as the 
control pair GABAB2RRluc and AT1RYFP led to a low and linear distribution, the specificity of the saturation (hyper-
bolic) assay for the A2ARRluc and AT1RYFP pair could be established (Fig. 1b). Overall, these results demonstrate 
that AT1R and A2AR form heteromers in living HEK-293T cells.
Structure of AT1R/A2AR heteromer. Computational modeling, protein-protein docking, and MD simu-
lations were used to probe the interaction between AT1R and A2AR, and determine their most likely heteromeric 
arrangement. Initially, AT1R and A2AR antagonists (losartan and istradefylline, respectively), were docked into 
their respective inactive-state receptor crystal structure using Autodock4.225. The corresponding best docked 
AT1R-losartan and A2AR-istradefylline complexes were then embedded in lipid bilayer membranes and sub-
jected to MD simulations of 250 ns and 500 ns, respectively, where both bound antagonists were observed to 
stabilize. In particular, in AT1R, ARG167, located on extracellular loop 2 (ECL2) above the orthosteric pocket, 
was observed to make H-bonds with losartan at both ends of the ligand (see SI Fig. 1) in a similar manner 
to that observed in the AT1R crystal structure containing bound olmesartan26. Likewise, in A2AR, ASN253 
(ASN6.55 in Ballesteros-Weinstein numbering27) made an H-bond with istradefylline in a similar manner to other 
co-crystallized A2AR xanthine antagonists28 (Fig. S1).
As both AT1R and A2AR are thought to form functional homodimers at the cell surface29–35, we investigated the 
likely structure and behavior of these respective homodimers with bound antagonists, prior to investigating het-
eromeric interactions. In order to do this we utilized the A2AR homodimer crystal structure with co-crystallized 
antagonist36 as a structural guide for initializing AT1R-losartan and A2AR-istradefylline homodimer models. This 
dimeric crystal structure is observed to contain an interface between TM4 and TM5 helices of each monomer, 
with TM4 of one monomer interacting with TM5 of the other, and vice versa36. Initial AT1R and A2AR homod-
imer models were refined with protein-protein docking using the ROSIE webserver37, each consisting of two 
antagonist-bound receptors in the same MD-generated conformation (see above). Following protein-protein 
docking, the A2AR and AT1R homodimers were subjected to further MD simulations of 1.5 μs and 750 ns, 
respectively. During these simulations, both AT1R and A2AR homodimers were seen to form significant inter-
actions via their TM4 and TM5 helices, respectively, with considerable contact between monomers, indicative 
of energetically stable dimers (Fig. S2). In addition, the respective bound antagonists remained stably bound in 
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each participating monomer, with all receptor subunits maintaining an inactive state. From these results, it was 
inferred that the antagonist-bound homodimeric states of AT1R and A2AR are stable in silico, and likely form the 
minimum constituents that participate in cross-receptor heteromeric interaction.
As other described heteromeric interactions involving A2AR fit a heterotetramer model38, 39, and as MD simu-
lations of AT1R and A2AR homodimers suggest their respective stability, we investigated heterotetrameric interac-
tions between the two receptor homodimers. As there is no crystal structure for GPCRs in tetrameric formation, 
we performed extensive protein-protein docking with ROSIE to identify the highest possible scoring interaction 
of AT1R and A2AR homodimers (see Methods). The “best” conformation identified a tetramer with cross-receptor 
interfaces involving TM5 and TM6 of one receptor with TM1 and TM2 of the other, and vice versa (Fig. 2). In 
order to assess the stability of the proposed interaction, the heterotetramer complex was subjected to an MD sim-
ulation in a membrane for 2 µs. Results show the receptors progressively stabilized (RMSD curve in Fig. S3) and 
enhanced their interaction, whilst maintaining the original tetrameric configuration (Fig. 2). Furthermore, the 
respective AT1R and A2AR homodimers remained stable and unperturbed within the tetramer, maintaining their 
respective inactive states. In conclusion, stable heterotetrameric interaction between AT1R and A2AR is plausible 
at a molecular level and compatible with bound antagonists, losartan and istradefylline.
Functional consequences of the AT1R and A2AR oligomerization. The formation of AT1R-A2AR 
complexes in transfected cells suggests that there might exist a functional coupling between these two receptors. 
Thus, we assessed the impact of A2AR expression on AT1R-mediated intracellular Ca2+ mobilization from internal 
stores by means of Fluo4 determinations. Thus, in Fluo4 loaded cells expressing AT1R alone, the activation with 
angiotensin II increased intracellular Ca2+ (Fig. 3a, red trace), as expected. Interestingly, in cells co-expressing 
AT1R and A2AR, the angiotensin II-mediated intracellular Ca2+ mobilization was boosted (Fig. 3a, blue trace). 
Indeed, in cells expressing only A2AR, a residual and not significant effect of angiotensin II was observed, prob-
ably because of the endogenous expression of AT1R in HEK-293T cells (Fig. 3a, black trace). Quantification of 
the results (Fig. 3c) demonstrated a significant [F (2,6) = 8.40 (P < 0.05)] difference between the experimental 
groups assessed, thus a significant (P < 0.05) increase in the AT1R-mediated intracellular calcium accumulation 
Figure 1. AT1R and A2AR physically interact in HEK-293T cells. (a) Co-distribution of AT1R and A2AR in 
HEK-293T cells. Transiently transfected HEK-293T cells with AT1RYFP (red) and A2ARCFP (green) were fixed 
and observed by confocal microscopy. Co-distribution (yellow) is shown in the merge image. Scale bar: 10 µm. 
(b). Direct interaction between AT1 and A2A receptors. BRET saturation curves in HEK-293T cells expressing 
A2ARRluc and AT1RYFP (blue) or GABAB2RRluc and AT1RYFP (red). Plotted on the x-axis is the fluorescence value 
obtained from the YFP, normalized with the luminescence value of Rluc-tagged vectors 10 min after benzyl-
coelenterazine incubation. Results are expressed as mean ± SEM (n = 3, in triplicate).
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 1857  | DOI:10.1038/s41598-017-02037-z
in AT1R-A2AR cells was observed (Fig. 3c). These results suggest that a functional interplay between AT1R and 
A2AR might exist upon expression in heterologous cells.
AT1R and A2AR heteromers are expressed in mouse striatum. Once demonstrated that AT1R and 
A2AR assemble into functionally interacting complexes in living cells, we aimed to determine the existence of 
AT1R/A2AR heteromers in native tissue, namely the striatum. To this end, we first conducted immunofluores-
cence experiments to assess the expression levels and distribution of both AT1R and A2AR in mouse striatum. 
Interestingly, both receptors showed a high degree of co-distribution throughout the striatal neuropil (Fig. 4a, 
upper panels) and eventually within the medium spiny neurons (MSN) cell bodies (Fig. 4a, lower panels). 
Importantly, the myelinated fiber bundles that penetrate the striatum were visible as dark (not stained) structures 
within the stained neuropil (Fig. 4a, upper panel). These results give rise to the possibility that these two receptors 
might be forming heteromers under native conditions. Subsequently, to confirm the existence of AT1R/A2AR 
heteromers in the striatum we implemented the P-LISA approach, a well described technique providing enough 
Figure 2. Conformational arrangement of AT1R/A2AR heterotetramer. Model generated by protein-protein 
docking and 2 μs MD simulation. (a) Top view of tetramer (AT1R in blue, A2AR in green, losartan in purple and 
istradefylline in brown). (b) Side view of interaction between A2AR and AT1R.
Figure 3. A2AR expression potentiates AT1R functioning. (a) Representative Angiotensin II-mediated 
intracellular Ca2+ accumulation determined by Fluo4 assay. HEK-293T cells were transiently transfected with 
A2AR (black trace), AT1R (red trace) and A2AR + AT1R (blue trace). Cells were loaded with Fluo4-NW dye and 
challenged with Angiotensin II (50nM). The [Ca2+]i dynamics is shown as change in fluorescence of the Fluo4 
signal (F) expressed as percentage of the maximal Ca2+ influx elicited by ionomycin (Fi) in each experimental 
conditions. (b) Quantification of the AT1R-mediated [Ca2+]i accumulation measured by Fluo4. The integrated 
area under the curve (AUC) of the normalized AT1R-mediated Fluo4 signal (F) is expressed as percentage of 
the corresponding ionomycin signal (Fi) for each transfection. The data are expressed as the mean ± SEM of 
three independent experiments performed in triplicate. The asterisk indicates statistically significant differences 
(**P < 0.01, ***P < 0.001; 1-way ANOVA with a Newman-Keuls post-hoc test).
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sensitivity to evaluate receptor’s close proximity within a named GPCR oligomer in native conditions40. Thus, by 
using proper antibody combinations, the AT1R/A2AR heteromer expression in mouse striatum was addressed by 
P-LISA assays. Indeed, red dots reflecting a positive P-LISA signal was observed in the striatum of wild-type mice 
(Fig. 4b), thus allowing the visualization of the AT1R/A2AR receptor-receptor interaction. Interestingly, in striatal 
slices from the A2AR-KO mice the P-LISA signal was negligible (Fig. 4b), thus reinforcing the specificity of our 
P-LISA assay. Indeed, when the P-LISA signal was quantified the wild-type animal showed 4 ± 0.5 dots/nuclei 
while the A2AR-KO displayed only 1 ± 0.2 dots/nuclei under the same experimental conditions. Thus, a marked 
and significant (P < 0.005) reduction in the P-LISA signal was observed in the A2AR-KO striatal slices. Taken 
together, data gathered from our P-LISA experiments strongly support the existence of AT1R/A2AR heteromers 
in the mouse striatum.
Functional interplay between AT1R and A2AR in an animal model of TD. A2AR-containing oli-
gomers, including A2AR/D2R41, are thought to be involved in the control of locomotor function both in normal 
Figure 4. Detection of AT1R and A2AR proximity in mice striatal sections. (a) Immunohistochemistry 
detection of AT1R and A2AR in mice striatum. Representative confocal microscopy images of AT1R (red) and 
A2AR (green) immunoreactivities in the striatum are shown. Lower panels show a magnification of the square 
area shown in the upper panel. Arrows indicate potential location of medium spiny neurons (MSN) cell bodies. 
Superimposition of images revealed a high receptor co-distribution in yellow (merge). Scale bars: 350 μm (upper 
panels) and 10 μm (lower panels). (b) Photomicrographs of dual recognition of AT1R and A2AR with P-LISA. 
Representative images from wild-type (left) and A2AR-KO (right) mice striatum. (c) Quantification of P-LISA 
signals for AT1R and A2AR proximity confirmed the significant difference of P-LISA signal density between wild 
type and A2AR-KO mice (***P < 0.001). Values in the graph correspond to the mean ± SEM (dots/nuclei) of at 
list three animals and 5 images per animal. Scale bar: 10 μm.
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and pathological conditions42, 43. However, although A2AR has been linked to neuroleptic-induced TD44, 45, its 
impact on this syndrome is still ambiguous46. Consequently, we sought to investigate whether the AT1R/A2AR 
heteromer might play a role in TD. We took advantage of the vacuous chewing movement (VCM) model of TD in 
mice. Interestingly, administration of the AT1R antagonist losartan dose-dependently reduced reserpine-induced 
VCM (Fig. 5a). Similarly, administration of the A2AR antagonist istradefylline dose-dependently reduced 
reserpine-induced VCM (Fig. 5b). Subsequently, we investigated whether co-treatment at sub-effective low doses 
of AT1R and A2AR antagonists would elicit a significant reduction of VCM in our reserpine-induced TD ani-
mal model. Therefore, for combination treatment, 0.05 mg/kg of losartan and 0.03 mg/kg of istradefylline were 
selected as they were not effective in reducing VCM. Noteworthy, the combined treatment produced a significant 
(P < 0.05) reduction in VCM (Fig. 5c), thus demonstrating a synergistic interaction between both drugs. Overall, 
these results suggest that co-treatment with AT1R and A2AR antagonists at sub-effective low doses is a useful ther-
apeutic approach for TD management.
Finally, in an attempt to ascertain the role of AT1R/A2AR oligomers in the synergistic effect observed upon 
receptor antagonist co-treatment, we assessed the efficacy of the VCM sub-effective losartan dose in mice lack-
ing the A2AR (i.e. A2AR-KO mice). Interestingly, the low dose of losartan (0.05 mg/kg) was able to significantly 
(P < 0.05) reduce the number of VCM in the A2AR-KO mice (Fig. 5d). Hence, in the absence of A2AR the effi-
cacy of losartan was higher, thus indicating that AT1R/A2AR heteromers are crucial for finely modulating TD. 
Collectively, these results suggest that AT1R and A2AR functionally interact in vivo and that this functional inter-
play may be provided by the existence of AT1R/A2AR oligomers.
Discussion
TD is a serious motor side effect associated to long-term treatment with neuroleptics47. Notably, D2R occu-
pancy and its transience to occupation have been identified as a potential mechanistic substrate to develop 
antipsychotic-induced TD48. Indeed, D2R-mediated control of motor function has been related to the ability of 
this receptor to oligomerize with other GPCRs in general49 and with the A2AR in particular42, 43, 50. Also, in the 
brain, dopaminergic neurotransmission can be modulated by AII through AT1R. Thus, AT1R blocking precludes 
AII-mediated dopamine release51, 52. Furthermore, a functional interaction between angiotensin and dopamine 
Figure 5. Effect of AT1R and A2AR blocking in the TD animal model. The effect of different doses of losartan 
(a) or istradefylline (b) on total vacuous chewing movements (VCM) in the reserpine-based animal model of 
TD in mice was monitored during 10 min. (c) Effects of sub-effective dose co-administration (i.p.) of losartan 
(0.05 mg/ml) and istradefylline (0.03 mg/ml) in the VCM of TD animal model. (d) Effect of losartan in the VCM 
of TD animal model performed in A2AR-KO mice. Results are represented as the mean ± SEM (n = 10 animals). 
*P < 0.05 compared to the vehicle group (one-way ANOVA, followed by Newman-Keuls test).
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receptors in the striatum and substantia nigra53, 54, together with the formation of D2R and AT1R heteromers in the 
striatum has been described17. Based on these data, we decided to explore a possible direct interaction between 
AT1R and A2AR, and revealed for the first time the existence of AT1R/A2AR oligomers in the striatum and its 
implications in TD.
Our experimental data shows that AT1R and A2AR form heteromers both in co-transfected cells and in mouse 
striatum. This feature is especially strengthened by our in-silico analysis, which has predicted a heterotetrameric 
receptor arrangement that was stable during 2 μs of MD simulation. The “best” receptor-receptor interface identified 
for the AT1R/A2AR heterotetramer involves TM5 and TM6 of one receptor with TM1 and TM2 of the other, and 
vice versa, while in the respective homodimers the TM4 of one monomer interactac with TM5 of the other, and vice 
versa. Interestingly, the D2R/A2AR heterodimeric interface has been postulated to be formed by the TM4 and TM5 
of D2R interacting with TM4 and TM5 of the A2AR49, 55. Therefore, when considering a putative AT1R/D2R/A2AR 
oligomer new in-silico analysis will be needed to accurately determine TM-TM contacts and receptor rearrange-
ment defining AT1R/D2R/A2AR oligomer stoichiometry. Overall, this information will be extremely valuable when 
assessing potential multimodal TD pharmacotherapeutic interventions based on drugs targeting these receptors.
The AT1R/A2AR oligomerization was shown to elicit functional consequences, since co-expression with A2AR 
boosted AT1R signaling. This AT1R gain of function may most likely result from an A2AR-mediated AT1R increased 
cell surface targeting, as was previously reported56. Alternatively, an A2AR-mediated direct trans-activation of 
AT1R could not be excluded, as has been described for other A2AR-containing oligomers41. Thus, further work 
is needed to elucidate the precise molecular mechanism behind this AT1R/A2AR oligomer-dependent AT1R gain 
of function. Nevertheless, our main purpose consisted of ascertaining the in vivo implications of the AT1R/A2AR 
oligomer formation, which is the cornerstone when describing a new GPCR oligomer57. Indeed, our P-LISA data 
strongly supported the existence of AT1R/A2AR heteromers in the mouse striatum, thus warranting the need to 
assess the impact of this oligomer in behaving animals. Accordingly, we demonstrated an unprecedented syner-
gism of AT1R and A2AR antagonists on the control of involuntary mandibular movements induced by reserpine 
in an animal model of TD. Thus, co-treatment with AT1R and A2AR antagonists at sub-effective low doses robustly 
(>60%) reduced reserpine-mediated VCM. Certainly, this makes this multimodal pharmacological approach an 
attractive solution for TD management.
The striatum is considered a pivotal brain region, since it receives projections from other basal ganglia areas 
and from many other brain regions involved in motor and non-motor functions, such as the motor cortex, the pre-
frontal cortex and the hippocampus58, 59. Indeed, both the renin-angiotensin and the adenosinergic systems play an 
important role in controlling the striatal function. Thus, the ability of AT1R and A2AR to heteromerize in the stria-
tum might constitute a way of fine-tuning multiple receptor-signaling pathways harmonizing dopaminergic neuro-
transmission. Therefore, the AT1R/A2AR oligomer could be envisaged as a potential drug target for striatum-related 
adverse motor dysfunctions associated to therapy, including TD and L-DOPA induced dyskinesia (LID). Indeed, 
A2AR antagonists have been postulated and licensed as antiparkinsonian drugs60 and eventually studied in the man-
agement of LID61. Furthermore, A2AR has been linked to neuroleptic-induced TD44, 45, although with some debate46. 
Similarly, preclinical studies have demonstrated that blockade of AT1R reduces LID62. It is assumed that these A2AR- 
and AT1R-mediated anti-LID effects are related to their ability to heteromerize with D2R17, 24 and thus controlling 
dopaminergic neurotransmission. However, it could be speculated that AT1R and A2AR might control D2R function 
through functional AT1R/D2R/A2AR-containing complexes in GABAergic striatopallidal neurons. A number of facts 
support this last statement: i) the high and selective co-expression of AT1R, D2R and A2AR in these particular cells; 
ii) the demonstration of A2AR/D2R, AT1R/D2R and AT1R/A2AR heteromers; and iii) the existence of strong multiple 
interactions between the three receptors. In conclusion, the demonstration of their simultaneous physical interac-
tion may constitute a novel and very attractive target for developing new drugs in the management of pathologies in 
which these receptors play a key role, such as TD.
Methods
Reagents. The primary antibodies used were: rabbit anti-AT1R polyclonal antibody (Abcam, Cambridge, 
UK), and mouse anti-A2AR monoclonal antibody (Millipore, Billerica, MA, USA). The secondary antibodies 
were: horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Pierce Biotechnology, Rockford, IL, USA) 
and Cy3-conjugated donkey anti-mouse IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, 
USA). The ligands used were: losartan (Abcam); angiotensin II, istradefylline (KW-6002), reserpine and ionomy-
cin from Sigma-Aldrich (St. Louis, MO, USA).
Plasmid constructs. To perform co-localization and BRET experiments, the A2AR constructs containing 
a cyan fluorescent protein (CFP; A2ARCFP), or the Renilla luciferase (Rluc; A2ARRluc) were used. The AT1R and 
GABAB2 receptor constructs containing a yellow fluorescent protein (YFP; AT1RYFP, GABAB2RYFP) were cloned, 
as previously described63.
Animals. CD-1 mice (Charles River Laboratories and from the central animal facility of Federal University 
of Santa Catarina) and A2AR-KO mice developed in a CD-1 genetic background64 (animal facility of University 
of Barcelona) weighing 20–25 g were used. The University of Barcelona and Federal University of Santa Catarina 
Committee on Animal Use and Care approved the protocol. Animals were housed and tested in compliance with the 
guidelines described in the Guide for the Care and Use of Laboratory Animals65 and following the European Union 
directives (2010/63/EU). All efforts were made to minimize animal suffering and the number of animals used. All 
animals were housed in groups of five in standard cages with ad-libitum access to food and water and maintained 
under 12 h dark/light cycle (starting at 7:30 AM), 22 °C temperature, and 66% humidity (standard conditions).
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Cell culture. Human embryonic kidney (HEK)-293T cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) (Sigma-Aldrich) supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/mL 
streptomycin, 100 mg/mL penicillin and 5% (v/v) fetal bovine serum at 37 °C and in an atmosphere of 5% CO2. 
HEK-293T cells growing in 25 cm2 flasks or six-well plates containing 18 mm coverslips were used for western 
blot and fluorescence imaging, respectively. They were transiently transfected with the cDNA encoding the spec-
ified proteins using Polyethylenimine (Polysciences, Inc. Warrington, PA, USA).
Fixed brain tissue preparation. Mice were anesthetized and perfused intracardially with 100–200 ml 
ice-cold 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS; 8.07 mM Na2HPO4, 1.47 mM KH2PO4, 
137 mM NaCl, 0.27 mM KCl, pH 7.2). Brains were post-fixed in the same solution of PFA at 4 °C during 12 h. 
Coronal sections (25 μm) were processed using a vibratome (Leica Lasertechnik GmbH, Heidelberg, Germany). 
Slices were collected in Walter’s Antifreezing solution (30% glycerol, 30% ethylene glycol in PBS, pH 7.2) and kept 
at −20 °C until processing.
Bioluminescence resonance energy transfer measurements. Bioluminescence resonance energy 
transfer (BRET) experiments in HEK-293T cells were performed as previously described66. In brief, HEK-293T 
expressing the indicated constructs were rapidly washed, detached, and resuspended in HBSS buffer (137 mM 
NaCl, 5 mM KCl, 0.34 mM Na2HPO4, 0.44 mM KH2PO4, 1.26 mM CaCl2, 0.4 mM MgSO4, 0.5 mM MgCl2, 10 mM 
HEPES, pH 7.4) containing 10 mM glucose. Cell suspensions (20 μg of protein) were distributed in 96-well 
microplate plates, 5 μM h-coelenterazine (NanoLight Technology, Pinetop, AZ, USA) was added and BRET 
determined in a POLARstar Optima plate-reader (BMG Labtech, Durham, NC, USA) as previously described66.
Intracellular calcium determination. The AT1R-mediated intracellular Ca2+ accumulation was assessed 
by Fluo4-NW Calcium Assay Kit (Invitrogen, Carlsbad, CA, USA). Thus, transiently transfected HEK-293T cells 
were lifted and plated in 96-well black plates with transparent bottoms. Cells were incubated with the Fluo4-NW 
following the instructions of the manufacturer and washed with HBSS. Fluorescence signals were measured at 
530 nm during 60 s while injecting Angiotensin II (50 nM) and ionomycin (5 μM) at seconds 5 and 40 respectively, 
using a POLARstar Optima plate-reader (BMG Labtech). The specific Angiotensin II-induced Fluo4 signal (F) 
was expressed as percentage of the signal elicited by ionomycin (Fi) in each set of experimental conditions67.
Immunohistochemistry. Previously collected slices were washed three times in PBS, permeabilized 
with 0.3% Triton X-100 in PBS for 2 hours and rinsed back three times more with wash solution (0.05% Triton 
X-100 in PBS). The slices were then incubated with blocking solution (10% NDS in wash solution; Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA, USA) for 2 h at R.T. and subsequently incubated with the 
primary antibodies overnight at 4 °C. After two rinses (10 min each) with 1% NDS in wash solution, sections 
were incubated for 2 h at R.T. with the appropriate secondary antibodies conjugated with Alexa dyes (Invitrogen, 
Carlsbad, CA, USA), then washed (10 min each) two times with 1% NDS in wash solution and two more times 
with PBS, and mounted on slides. Fluorescence striatal images were obtained using a Leica TCS 4D confocal 
scanning laser microscope (Leica Lasertechnik GmbH).
Proximity ligation in situ assay. Duolink in situ PLA detection Kit (Olink Bioscience, Uppsala, Sweden) 
was performed in a similar manner as immunohistochemistry explained above until the secondary antibody 
incubation step. The following steps were performed following the manufacturer’s protocol, as previously 
described24, 40. Fluorescence images were acquired on a Leica TCS 4D confocal scanning laser microscope (Leica 
Lasertechnik GmbH) using a 60x N.A. =1.42 oil objective from the selected area. High-resolution images were 
acquired as a z-stack with a 0.2 μm z-interval with a total thick of 5 μm. Nonspecific nuclear signal was eliminated 
from PLA images by substracting DAPI labeling. Analyze particle function from Image J (NIH) was used to 
count particles larger than 0.3 μm2 for PLA signal and larger than 100 μm2 to discriminate neuronal from glia 
nuclei68. For each image a number of oligomer particles and neuron nuclei was obtained and ratio among them 
was calculated.
Computational modeling. Ligand docking. Crystal structures of AT1R (PDB id: 4ZUD) and A2AR (PDB 
id: 4EIY) were converted into apo wt forms by removing co-crystallized ligands and non-native fusion proteins 
i.e. cytochrome b562, building missing intracellular and extracellular loop sections with MODELLER v9.1469, and 
energy minimizing in the AMBER14SB force-field70 with CHIMERA v1.10.271. The AT1R antagonist losartan and 
A2AR antagonist istradefylline were downloaded from PubChem72, energy-minimized in AMBER14SB force-field 
with CHIMERA and docked into respective receptor structures with Autodock4.225 using default parameters. 
Grid points were generated to cover total orthosteric pocket volumes. The final docking conformations of losartan 
and istradefylline represented top hits identified by best predicted affinity (nM). These were checked to be con-
sistent with previously reported binding modes of relevant co-crystallized antagonists26, 28. In particular, losartan 
was docked to interact with Arg167 and istradefylline was docked to interact with Asn253. Subsequent energy 
minimization of docked structures was performed with CHIMERA in the AMBER-14SB force-field.
Protein-protein docking. For generating homodimers of respective receptors: AT1R and A2AR with bound antag-
onists, two molecular dynamics (MD)-generated receptor-ligand monomers (see MD methods) of either AT1R 
or A2AR, in each case, were superimposed onto the A2AR homodimer crystal structure (PDB id: 4EIY), yielding 
an initial homodimer model, which was then submitted to the ROSIE webserver37 for protein-protein docking. 
For both AT1R and A2AR, the best docked homodimer was identified by three factors: best possible ROSETTA 
interface score (I_sc), lowest possible RMSD in relation to initial model, and acceptable membrane-compatible 
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orientation. For construction of an AT1R-A2AR heterotetramer, two initial tetrameric arrangements were man-
ually generated by combining respective MD-generated AT1R and A2AR homodimers (see MD section) in alter-
native ways: (i) where homodimers are arranged side-to-side in a rectangular-like configuration, where each 
homodimer subunit interacts with a subunit of the other homodimer (by respective TM1/2–5/6 helices), (ii) 
where homodimers are partially displaced with respect to one another creating a parallelogram-like configura-
tion, where both subunits of one homodimer interact with a single subunit of the other homodimer (by respective 
TM4/5 helices). Both these alternative configurations were submitted to the ROSIE webserver for identifica-
tion of the best possible tetrameric arrangement according to the same criteria implemented previously. For all 
protein-protein docking runs executed on the ROSIE webserver, default local parameters were used, i.e. perturba-
tion of 3 Å between proteins, 8° of tilt, and 360° rotation around protein centers, with generation of 1000 docking 
solutions per case.
Molecular dynamics system setup. Five different systems were generated using the CHARMM-GUI web-based 
interface73, each in a POPC membrane and solvated with TIP3P water molecules: AT1R monomer with bound 
losartan, A2AR monomer with bound istradefylline, AT1R homodimer with bound losartan, A2AR homodimer 
with bound istradefylline, and AT1R-A2AR heterotetramer with bound antagonists. All receptor structures were 
orientated according to the OPM database74 entry: 4eiy. Charge neutralizing ions (0.15 M KCl) were introduced 
to each system. Parameters of membrane, water and protein were automatically generated by CHARMM-GUI73 
according to CHARMM36 force-field75 with ligand parameters automatically generated according to 
CHARMM36 General Force Field76–78.
Molecular dynamics simulations. Molecular dynamics (MD) simulations of AT1R and A2AR were performed 
using the CHARMM36 force-field75 with ACEMD79 on specialized GPU-computer hardware, totaling 5 μs across 
systems. In detail, monomer AT1R/A2AR systems were equilibrated for 20 ns at 300 K and 1 atm, while AT1R/A2AR 
homodimers and heterotetramer systems were equilibrated for 50 ns under same conditions. During equilibra-
tion, positional harmonic restraints on protein and antagonist heavy atoms were progressively released over the 
first 8 ns and then continued without constraints. After equilibration, AT1R and A2AR monomers were subjected 
to unbiased production runs of 250 ns and 500 ns under same conditions, respectively. Likewise, AT1R and A2AR 
homodimers were subjected to unbiased production runs of 750 ns and 1.5 μs, respectively. The AT1R/A2AR het-
erotetramer was subjected to an unbiased production run of 2 μs. Simulation trajectories were analyzed using 
VMD software v1.9.280.
Reserpine-induced vacuous chewing movements. The VCM model of TD48 was induced in mice 
through two subcutaneous (s.c.) reserpine injections (1 mg/kg) administered with an interval of 48 h. Twenty-four 
hours after the last reserpine administration, mice were treated by intraperitoneal (i.p.) route with losartan (0.05–
50 mg/kg) and/or istradefylline (0.03–0.06 mg/kg). VCM parameters were evaluated as previously described81 but 
with some modifications. Thus, the evaluation of VCM frequency consists of a manual counting of continuous 
single mouth openings in a vertical plane, not directed to a physical material. Mirrors were placed on the table 
and behind the glass cylinder (Ø 19 cm and 22 cm height) to allow observation of the orofacial movements when 
mice were not facing the observer. The evaluation of this parameter during 10 min was performed by a blind 
observer, 30 min after the pharmacological treatments administered 24 h after the second reserpine injection81.
Statistics. The number of samples (n) in each set of experimental conditions is indicated in figure legends. 
Statistical analysis was performed by one-way ANOVA followed by Newman-Keuls post-hoc test or Student’s 
t-test when appropriate. Statistical significance was considered at P < 0.05.
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